Document is current
Any future updates will be listed below
-
Authors
Miyamoto, Kenichi https://orcid.org/0000-0002-1848-2760
Watanabe, Takashi
Wakabayashi, Masashi
Nakamura, Kenichi
Watanabe, Yuko
Maruyama, Dai
Tobinai, Kensei
Tsukasaki, Kunihiro
Fukuda, Haruhiko
-
Funding
Funding for this research was provided by:
the National Cancer Center Research and Development Fund (26-A-4, 29-A-3)
- License Information
-
More Information
Article History
Received: 2 May 2020
Accepted: 1 October 2020
First Online: 28 October 2020
Compliance with ethical standards
:
: KM: No conflicts to disclose. TW: Received honoraria from Bristol-Meyers Squibb, AstraZeneca Pharmaceutical, and Chugai Pharmaceutical, received funding resources from Takara Bio Inc, United Immunity, Co., Ltd., and BrightPath Biotherapeutics Co., Ltd. MW: No conflicts to disclose. KN: No conflicts to disclose. YW: No conflicts to disclose. DM: Received patent licensing fees from Mundi Pharma, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, received research funding from Mundi Pharma, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Celgene, AbbVie. KT: Advisory role of Mundi Pharma, Zenyaku Kogyo, HUYA Bioscience International, Daiichi Sankyo, Ono Pharmaceutical, Takeda Pharmaceutical, received honoraria from Mundi Pharma, Zenyaku Kogyo, HUYA Bioscience International, Eisai, Kyowa Kirin, Ono Pharmaceutical, Takeda Pharmaceutical, Celgene, and Chugai Pharmaceutical, received research funding from Mundi Pharma, Kyowa Kirin, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Celgene, Takeda Pharmaceutical, AbbVie. KT: Advisory role of HUYA Bioscience International, Daiichi Sankyo, Ono Pharmaceutical, received honoraria from Mundi Pharma, Eisai, Kyowa Kirin, Bayer, Takeda Pharmaceutical, Celgene, and Chugai Pharmaceutical, received research funding from Daiichi Sankyo, HUYA Bioscience International, Chugai Pharmaceutical, Eisai, Bayer, Celgene. HF: No conflicts to disclose.
